• Login
    View Item 
    •   NWU-IR Home
    • Research Output
    • Faculty of Health Sciences
    • View Item
    •   NWU-IR Home
    • Research Output
    • Faculty of Health Sciences
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Drug bioavailability enhancing agents of natural origin (bioenhancers) that modulate drug membrane permeation and pre-systemic metabolism

    Thumbnail
    View/Open
    Drug_bioavailability.pdf (2.187Mb)
    Date
    2019
    Author
    Peterson, Bianca
    Weyers, Morné
    Steenekamp, Jan H.
    Steyn, Johan D.
    Gouws, Chrisna
    Hamman, Josias H.
    Metadata
    Show full item record
    Abstract
    Many new chemical entities are discovered with high therapeutic potential, however, many of these compounds exhibit unfavorable pharmacokinetic properties due to poor solubility and/or poor membrane permeation characteristics. The latter is mainly due to the lipid-like barrier imposed by epithelial mucosal layers, which have to be crossed by drug molecules in order to exert a therapeutic effect. Another barrier is the pre-systemic metabolic degradation of drug molecules, mainly by cytochrome P450 enzymes located in the intestinal enterocytes and liver hepatocytes. Although the nasal, buccal and pulmonary routes of administration avoid the first-pass effect, they are still dependent on absorption of drug molecules across the mucosal surfaces to achieve systemic drug delivery. Bioenhancers (drug absorption enhancers of natural origin) have been identified that can increase the quantity of unchanged drug that appears in the systemic blood circulation by means of modulating membrane permeation and/or pre-systemic metabolism. The aim of this paper is to provide an overview of natural bioenhancers and their main mechanisms of action for the nasal, buccal, pulmonary and oral routes of drug administration. Poorly bioavailable drugs such as large, hydrophilic therapeutics are often administered by injections. Bioenhancers may potentially be used to benefit patients by making systemic delivery of these poorly bioavailable drugs possible via alternative routes of administration (i.e., oral, nasal, buccal or pulmonary routes of administration) and may also reduce dosages of small molecular drugs and thereby reduce treatment costs
    URI
    http://hdl.handle.net/10394/32101
    https://www.mdpi.com/1999-4923/11/1/33/pdf
    https://doi.org/10.3390/pharmaceutics11010033
    Collections
    • Faculty of Health Sciences [2404]

    Copyright © North-West University
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of NWU-IR Communities & CollectionsBy Issue DateAuthorsTitlesSubjectsAdvisor/SupervisorThesis TypeThis CollectionBy Issue DateAuthorsTitlesSubjectsAdvisor/SupervisorThesis Type

    My Account

    LoginRegister

    Copyright © North-West University
    Contact Us | Send Feedback
    Theme by 
    Atmire NV